Spencer Feldman

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment. For those with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), the first patients have been enrolled in […]

The GAP regimen did not improve overall survival in advanced biliary tract cancer compared with gemcitabine and cisplatin, and it led to increased toxicity. Among patients with newly diagnosed advanced biliary tract cancers (BTCs), the addition of taxane with the

Breyanzi showed significant efficacy and durable responses in adults with relapsed or refractory marginal zone lymphoma in the phase 2 TRANSCEND FL trial. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met

Regeneron’s BLA resubmission for linvoseltamab, a potential treatment for relapsed/refractory multiple myeloma, is under FDA review. For adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy or those who received three prior

Certain side effects following enfortumab vedotin associated with improved PFS in metastatic urothelial carcinoma: © magicmine – stock.adobe.com For patients with metastatic bladder or upper tract urothelial carcinoma who were treated with Padcev (enfortumab vedotin, EV), the presence of neuropathy,

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma. The U.S. Food and Drug Administration (FDA) received a new drug application (NDA) from Chimerix, which seeks

Low levels of circulating tumor DNA (ctDNA) may indicate a longer recurrence-free interval in patients with triple-negative breast cancer. Among patients with triple-negative breast cancer (TNBC), circulating tumor DNA (ctDNA) was detected most frequently on the initial test and at

An expert spoke about the effectiveness of two treatment combinations for patients with untreated CLL. In patients with chronic lymphocytic leukemia (CLL) who did not previously receive treatment, a combination of Imbruvica (ibrutinib) plus venetoclax chemotherapy showed promising outcomes compared

A real-world population of patients with a certain breast cancer subset showed that time to next treatment and treatment discontinuation was slightly higher with Orserdu. In patients with hormone receptor (HR)-positive or HER2-negative advanced breast cancer with an ESR1 mutation,

In 2003, 7-year-old Maggie Bushway started writing a book about her experience with brain cancer, while her father, Rob, began documenting their family’s story on a blog. Two decades later, Maggie, now 28, came across a box containing her dad’s